Medicon Pharmaceuticals, Inc.

Medicon Pharmaceuticals, Inc. is a privately held American drug development company based in Setauket, New York. It focuses on discovering and developing novel small-molecule agents for cancer, inflammation, and dermatological diseases. The company was founded by Dr. Basil Rigas, a physician-scientist who serves as President and CEO and who invented the compounds the company is developing. Medicon's scientific approach centers on a newly discovered mechanism of action that guides the rational synthesis of new classes of compounds. Its pipeline consists largely of chemically modified versions of already approved drugs, including modified nonsteroidal anti-inflammatory drugs (NSAIDs). The company states that its products demonstrate a large therapeutic window and negligible toxicity, with broad therapeutic properties. A lead example is OXT-328, a derivative of the NSAID sulindac. According to the company, OXT-328 displays superior efficacy and safety compared with conventional sulindac in numerous preclinical models. The key to these properties is the company's proprietary chemical modification and the resulting novel mechanism of action, which differs substantially from that of the parent compound. Medicon's mission is to produce effective agents with minimal or no toxicity and broad therapeutic properties. Its ongoing extensive preclinical testing is advancing lead compounds toward early clinical studies to obtain proof-of-concept. The company operates primarily in the United States and remains a private, research-stage enterprise.

Medicon Pharmaceuticals, Inc. is a privately held American drug development company located in Setauket, New York. The company was founded by Dr. Basil Rigas, a physician-scientist with experience in both academia and industry. Dr. Rigas invented the compounds that Medicon is developing and serves as the company's President and CEO. Medicon's research is built on a newly discovered mechanism of action that helps guide the rational synthesis of new classes of compounds. The company's mission is to produce effective agents with minimal or no toxicity and broad therapeutic properties. Its pipeline focuses on small molecules with antineoplastic and anti-inflammatory properties, most of which are chemically modified versions of already approved drugs. A central example of Medicon's approach is OXT-328, a derivative of the nonsteroidal anti-inflammatory drug (NSAID) sulindac. In numerous preclinical models, OXT-328 has displayed superior efficacy and safety compared with conventional sulindac. The company attributes these properties to its proprietary chemical modification and the resulting novel mechanism of action, which is very different from that of the parent compound. Medicon states that its products demonstrate a large therapeutic window and negligible toxicity. As of the available public information, Medicon remains a research-stage company. Its ongoing extensive preclinical testing is advancing lead compounds toward early clinical studies to obtain proof-of-concept. The company operates primarily in the United States.

• Medicon Pharmaceuticals is founded by Dr. Basil Rigas.

• The company develops OXT-328, a sulindac derivative, as a lead compound.

A research-stage pharmaceutical developer focused on low-toxicity, chemically modified small molecules with novel mechanisms of action for cancer, inflammation, and dermatological diseases.

• OXT-328

  A derivative of the NSAID sulindac that displays superior efficacy and safety compared with conventional sulindac in numerous preclinical models.

• Modified NSAIDs

  Chemically modified nonsteroidal anti-inflammatory drugs in the company's pipeline.

• Small-molecule antineoplastic and anti-inflammatory compounds

  Small molecules with antineoplastic and anti-inflammatory properties, most of which are chemically modified already approved drugs.

1. 1Home | mediconmpipharma.com
2. 2About | mediconmpipharma.com
3. 3Products | mediconmpipharma.com
4. 4Medicon Pharmaceuticals (United States) - Wikidatawikidata.org